A recent comprehensive Mendelian randomization study identified potential biomarkers in cerebrospinal fluid (CSF) and plasma for various types of dementia, including apolipoprotein ε2 (APOE2) for various dementias, Siglec-3 for AD in CSF, and CD33 for AD [2]. This evidence concerns the gene CD33 and Alzheimer disease.